论文部分内容阅读
目的:探讨甲泼尼龙治疗重症哮喘的临床疗效。方法:把我院从2015年9月至2017年4月收治的重症哮喘患者84例作为本次研究对象,随机把患者分为对照组与治疗组,2组各有42例患者,对照组应用氢化可的松治疗,治疗组应用甲泼尼龙治疗,比较两组患者的临床疗效。结果:治疗组治疗总有效率是95.24%,对照组治疗总有效率是76.19%,组间比较差异显著(P<0.05);治疗组治疗后PaO2与PaCO2水平要显著高于对照组与治疗前(P<0.05)。结论:重症哮喘应用甲泼尼龙治疗能够获得较好的临床疗效,值得临床推广应用。
Objective: To investigate the clinical efficacy of methylprednisolone in the treatment of severe asthma. Methods: 84 cases of severe asthma admitted from September 2015 to April 2017 in our hospital were selected as the object of this study. Patients were randomly divided into control group and treatment group, 42 patients in each group and 42 cases in control group Hydrocortisone treatment, the treatment group treated with methylprednisolone, the clinical efficacy of the two groups were compared. Results: The total effective rate of the treatment group was 95.24%, the total effective rate of the control group was 76.19%, the difference between the two groups was significant (P <0.05); PaO2 and PaCO2 levels in the treatment group were significantly higher than those in the control group and before treatment (P <0.05). Conclusion: The application of methylprednisolone in severe asthma can achieve better clinical curative effect, which is worthy of clinical application.